The HRE-Luc Reporter Cell Line-HeLa is a unique tool that aids researchers by providing a simple and accurate method to study the hypoxic response of cancer cells. This cell line is derived from human cervical cancer cells (HeLa cells) and is genetically engineered to express luciferase, a bioluminescent enzyme, under the control of a hypoxia response element (HRE). HRE is a regulatory DNA sequence that is activated under low oxygen or hypoxic conditions.
The key feature of the HRE-Luc reporter cell line HeLa is its ability to emit light in response to hypoxic conditions. When cells are starved of oxygen, it activates specific genes that allow the cells to adapt and survive. One of these genes is regulated by hypoxia-inducible factor (HIFA), which binds to the HRE and initiates the transcription of various adaptive genes. In this engineered cell line, the presence of luciferase under HRE control allows real-time monitoring of the hypoxic response by measuring the amount of light produced.
The growth of solid tumors is inevitably accompanied by hypoxia and angiogenesis. Understanding the true status of tissue hypoxia and angiogenesis during tumor progression will help further understand the tumor microenvironment and cancer treatment. Here, researchers used a hypoxia response element (HRE)-driven luciferase (LUC) reporter transfected cervical cancer cell line for hypoxia visualization. The hypoxia response activity of HRE-driven LUC was verified in HeLa cells and then monitored by bioluminescence imaging (BLI) through the HeLa-HRE-LUC tumor-bearing mouse model. An oxygen-sensitive nanoparticle was constructed for Ir(piq)3/IR780-loaded glycerol monooleate cubic liquid crystal material for phosphorescence-fluorescence imaging. Imaging results showed that the nanoparticles marking the hypoxic area overlapped with the BLI signal area detected by HRE-driven LUC in vivo, confirming that the hypoxia visualization platform can truly reflect the hypoxia level in vivo. The changes in deoxygenated/oxygenated hemoglobin detected by photoacoustic imaging reflect angiogenesis in vivo. Furthermore, the anticancer drug apigenin downregulated HIF-1α and VEGF under hypoxic conditions and inhibited tubule formation in vitro. The inhibitory effect was then validated in an in vivo hypoxia and angiogenesis visualization model.
Figure 1. Hypoxia-induced LUC expression in HeLa cells and establishment of a subcutaneous xenograft cervical tumor model in nude mice. (A) Construction of the recombinant lentiviral plasmid HRE-hCMVmp-LUC. (B) Relative activity ratio of HRE-LUC/RLUC in transient transfection experiments of HeLa cells treated with normoxia or hypoxia. (C) Relative activity ratio of HRE-LUC/RLUC in HeLa-HRE-LUC stable transfected cells treated with normoxia or hypoxia. (D) BLI of HeLa-HRE-LUC stable transfected cells after 24 h of hypoxia. (E) The semi-quantification of the cell bioluminescence intensity of (D). (F) BLI of the cancer model mouse inoculated with 103, 104, 105 and 106 HeLa-HRE-LUC cells. The area circled in red is the tumor. (G-H) The semi-quantification of the tumor bioluminescence intensity of (F) and (I). (I) BLI of the cancer model mice recorded at 1, 3, 8, 12, and 15 days. (Chen D, et al., 2023)
The HRE-Luc reporter cell line-HeLa has a variety of applications, particularly in biological research and drug discovery. Here are some of its main uses:
Hypoxia Studies - This cell line contains a luciferase reporter gene controlled by a hypoxia response element (HRE), which is activated under hypoxic conditions. Therefore, they are often used to study how cells respond to low oxygen levels.
Anticancer Drug Screening - They are frequently used in high-throughput screening platforms for new drugs. Specifically, the researchers used these cells to test compounds that could inhibit or activate the HRE, which is essential for cancer cells to survive under hypoxic conditions.
Gene Therapy Research - HRE-Luc Reporter Cell Line-HeLa can also be used for gene therapy research. It can help researchers track and quantify the effectiveness of a specific gene therapy by observing changes in the luminescence readout of a luciferase reporter gene.
Molecular Pathway Study - Activation of HRE is mediated through the HIF (hypoxia-inducible factor) pathway. Therefore, these cells are used to study this molecular pathway and the role of the various proteins involved.
Customer Reviews
Results are always reliable
I've been using the HRE-Luc Reporter Cell Line-HeLA for my hypoxia research, and the results have been consistently reliable. The luciferase activity is robust, making it easy to quantify the hypoxia-inducible factor (HIF) response.
Valuable tool
We've had great success using the HRE-Luc Reporter Cell Line-HeLa for screening potential HIF inhibitors. The luciferase assay is straightforward and yields consistent results, allowing us to identify promising compounds quickly.
United Kingdom
01/14/2023
High quality
As a researcher focused on cancer biology, the HRE-Luc Reporter Cell Line-HeLa has been invaluable in studying tumor hypoxia. The luciferase reporter provides a direct and quantifiable readout of HIF activity, and the HeLa cells are robust and easy to handle.
Write a Review